D.A. Davidson & CO. Buys 34,466 Shares of Zoetis Inc. $ZTS

Key Points

• D.A. Davidson increased its Zoetis stake by 225.4% in the third quarter, purchasing 34,466 additional shares and bringing its holdings to 49,760 shares valued at approximately $3.48 million.
• Zoetis recently reported quarterly EPS of $1.87, slightly above estimates, but revenue of $2.47 billion fell short of expectations and declined slightly year over year. The company also maintained fiscal 2026 EPS guidance of $6.15–$6.25.
• Investor sentiment remains mixed: Zoetis approved a new canine antibiotic and pays a quarterly dividend of $0.53 per share, while analysts’ average rating is “Hold” with an average price target of $93.79 amid weaker U.S. pet-care demand and reduced guidance.

D.A. Davidson & CO. raised its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 225.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,760 shares of the company's stock after buying an additional 34,466 shares during the period. D.A. Davidson & CO.'s holdings in Zoetis were worth $3,475,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in ZTS. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis during the 1st quarter worth approximately $28,000. Root Financial Partners LLC grew its holdings in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company's stock worth $30,000 after acquiring an additional 103 shares during the period. Wellington Grp LLC increased its stake in Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company's stock valued at $32,000 after purchasing an additional 267 shares in the last quarter. Global Assets Advisory LLC purchased a new position in Zoetis in the 1st quarter valued at approximately $38,000. Finally, University of Texas Texas AM Investment Management Co. purchased a new position in Zoetis in the 2nd quarter valued at approximately $25,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The FDA approved Convenia RTU, a ready-to-use, single-dose antibiotic for dogs. The product could strengthen Zoetis’ companion-animal portfolio and provide an additional commercial opportunity. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts expect Zoetis to potentially beat consensus estimates in its upcoming third-quarter report, with the company’s earnings setup and operating trends viewed as supportive. This is an expectation, not a reported result. Zoetis expected to beat earnings estimates
• Positive Sentiment: BTIG Research assigned a “buy” view before ending its coverage of Zoetis. The endorsement may reinforce the argument that the shares are undervalued, although the end of coverage reduces the ongoing value of that analyst relationship. BTIG Research ratings
• Neutral Sentiment: Recent market commentary highlights valuation compression versus animal-health peers IDEXX Laboratories and Elanco. Livestock and international sales have partly offset weaker U.S. pet-care demand, creating a possible recovery opportunity but not yet confirming a broad business rebound. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain cautious because lower guidance and softer U.S. pet-care demand could limit the pace of recovery, even as the new product approval and potential earnings beat provide near-term support.

Zoetis Stock Down 0.1%

Shares of NYSE:ZTS opened at $79.67 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $32.92 billion, a P/E ratio of 13.13, a P/E/G ratio of 1.18 and a beta of 0.67. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $144.83. The stock's fifty day simple moving average is $75.04 and its 200-day simple moving average is $93.64.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm's quarterly revenue was down .2% compared to the same quarter last year. During the same quarter last year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.15 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis's dividend payout ratio (DPR) is currently 34.93%.

Analysts Set New Price Targets

A number of analysts have commented on ZTS shares. HSBC decreased their target price on Zoetis from $140.00 to $95.00 and set a "buy" rating on the stock in a research report on Monday, July 6th. Morgan Stanley dropped their price target on Zoetis from $85.00 to $82.00 and set an "overweight" rating for the company in a research report on Thursday. Stifel Nicolaus cut their price target on Zoetis from $85.00 to $80.00 and set a "hold" rating for the company in a research note on Thursday, August 20th. BTIG Research dropped coverage on shares of Zoetis in a research report on Friday. They issued a "buy" rating on the stock. Finally, BNP Paribas Exane decreased their price objective on shares of Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 11th. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $93.79.

Zoetis Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company's product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.